Navigation Links
The Biosimilars Council Announces Chairman of the Board of Directors, Officers
Date:7/21/2015

WASHINGTON, July 21, 2015 /PRNewswire-USNewswire/ -- The Biosimilars Council, a division of the Generic Pharmaceutical Association (GPhA) that works to educate patients and health professionals and to ensure a positive regulatory and policy environment for patient access to biosimilar medicines, today announced the election of the first Chairman of its Board of Directors.

Dr. Bertrand C. Liang, Chief Executive Officer, Pfenex Inc., will be the inaugural Biosimilars Council Chairman. The other leadership roles are Vice Chairman John Pakulski, Executive Director and Head U.S. Biopharmaceutical Affairs, Sandoz, and Treasurer Bruce Lott, Vice President of State Government Relations and Global Biologics Policy, Mylan Inc.

"I am extremely excited to lead the Biosimilars Council efforts to collaborate with patients, health professionals, regulatory agencies and elected officials in order to ensure a positive environment for these promising medicines," said Liang. "Biosimilars are poised to play a critical role in our nation's health system — providing patients with safe, effective, more affordable alternatives to costly brand biologic therapies. As the Food and Drug Administration moves forward with its review of biosimilars applications, it is more important now than ever to establish an effective legal and regulatory foundation and ensure that patients and professionals are educated about these medicines. I look forward to working closely with the FDA and other agencies to create a pathway that encourages adoption of these life-impacting drugs."

The potential savings from biosimilars is great, according to experts cited in The Next Frontier for Access to Medicines: Biosimilars and Interchangeable Biologics, an educational handbook offered by the Biosimilars Council. Estimates from various economic impact studies pin the projected savings from $44 billion on the low end to as high as $250 billion over the first 10 years that only 11 of the most likely biosimilars are available to patients.

"GPhA and its Biosimilars Council remain focused on preserving and promoting access and savings from more affordable medicines," said Ralph G. Neas, President and CEO, GPhA. "The Biosimilars Council is an unrivaled resource for anyone seeking to navigate this emerging industry, build relationships and be directly involved in formative regulatory, reimbursement, political, and policy conversations."

The Biosimilars Council Board of Directors includes representatives from the following member companies:

• Amneal BioSciences, LLC 
• ApoBiologix
• Biocon
• Dr. Reddy's
• Momenta Pharmaceuticals, Inc. 
• Mylan Inc.
• Pfenex Inc.
• Sandoz
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceuticals USA
• Therapeutic Proteins International 
• Zydus Pharmaceuticals

About the Biosimilars Council

The Biosimilars Council works to ensure a positive regulatory, reimbursement, political and policy environment for patient access to biosimilar medicines, and will educate the public and patients about the safety and effectiveness of biosimilars. Areas of focus will include education, access, the nascent regulatory environment, reimbursement and legal affairs. Additional information is available at www.biosimilarscouncil.org.

About GPhA

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals fill 86 percent of the prescriptions dispensed in the U.S. but consume just 27 percent of the total drug spending. Additional information is available at gphaonline.org. Follow us on twitter: @gpha.

Contact: Steve Arnoff, 202.249.7113

Logo - http://photos.prnewswire.com/prnh/20150721/238878LOGO

 


'/>"/>
SOURCE The Biosimilars Council
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Biosimilars And Follow-On Biologics: World Market 2013-2023
2. Oncobiologics and inVentiv Health Form Strategic Partnership around Biosimilars
3. Market Research Reports: Biologics, Biosimilars, Bioseparation Systems for Biopharmaceutical Markets
4. New Primer Co-Authored by Novation Describes Potential Impact of Biosimilars on Pharmacy Practice; Opportunity for Hospitals to Manage Drug Expenditures
5. Janssen Pharmaceutical Companies of Johnson & Johnson Submit Citizen Petition to the U.S. FDA Regarding Naming of Biosimilars
6. Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020
7. Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Research Report, 2013 - 2020
8. Surveyed Physicians Expect to Choose Between Future Biosimilars Based on Robustness and Number of Clinical Trials
9. Europe Biosimilars Market & Pipeline Insight: 2014 Report
10. Conference: 6th Biosimilars Congregation 2015
11. Survey Published in AMCPs JMCP Finds Pharmacists Are Most Confident Substituting Interchangeable Biosimilars for Brand Biologics When Products Share Nonproprietary Name
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2018)... ... 2018 , ... American Vision Partners, one of the largest ... Eye Center, an affiliate of American Vision Partners, announced the strategic partnership with ... the quality of care for patients in the Mesa area by bringing more ...
(Date:12/8/2018)... , ... December 07, 2018 , ... ... Best Online Master's in Forensic Psychology Programs for 2019. They have identified ... of curriculum quality, program flexibility, affordability, and graduate outcomes. , Leveraging an exclusive ...
(Date:12/8/2018)... ... December 08, 2018 , ... The holidays can be ... the Gary Sinise Foundation’s Snowball Express program will host a five-day experience for ... retreat will offer fun and inspiring programs, encouraging critical peer-to-peer support for these ...
Breaking Medicine Technology:
(Date:12/6/2018)... ... December 06, 2018 , ... Tea infusions ... significantly faster than the drug most commonly used against the ailment—and with no ... Congo. The study’s authors, including a professor and two research associates at Worcester ...
(Date:12/5/2018)... CITY, Tenn. and DALLAS, Texas (PRWEB) , ... ... ... aesthetics team, again proved its leading SkinPen Precision device is setting a new ... of its record-setting Aesthetics Everything win. , Each year this award is presented ...
(Date:12/5/2018)... ... 05, 2018 , ... Northeast Delta Human Services Authority will ... Monroe Baptist Church, 210 Finks Hideaway Rd, Monroe, LA 71203. , The training ... educate and equip faith leaders to address substance abuse prevention, support and recovery ...
(Date:12/5/2018)... , ... December 05, 2018 , ... Dr. Jessica Allen ... treatment and LAPIP™ protocol for ailing dental implants in the Fort Collins area. Dr. ... treatment proven to regenerate the bone and tissues lost to gum disease. , "Gum ...
(Date:12/5/2018)... , ... December 05, 2018 , ... ... analytics on the healthcare provider market, announced today that it was ranked #184 ... North American companies with the highest growth in the fields of technology, media, ...
Breaking Medicine News(10 mins):